TY - JOUR
T1 - Genome-Editing Technologies in Adoptive T Cell Immunotherapy for Cancer
AU - Singh, Nathan
AU - Shi, Junwei
AU - June, Carl H.
AU - Ruella, Marco
N1 - Publisher Copyright:
© 2017, Springer Science+Business Media, LLC.
PY - 2017/12/1
Y1 - 2017/12/1
N2 - Purpose of Review: In this review, we discuss the most recent developments in gene-editing technology and discuss their application to adoptive T cell immunotherapy. Recent Findings: Engineered T cell therapies targeting cancer antigens have demonstrated significant efficacy in specific patient populations. Most impressively, CD19-directed chimeric antigen receptor T cells (CART19) have led to impressive responses in patients with B-cell leukemia and lymphoma. CTL019, or KYMRIAH™ (tisagenlecleucel), a CD19 CAR T cell product developed by Novartis and the University of Pennsylvania, was recently approved for clinical use by the Food and Drug Administration, representing a landmark in the application of adoptive T cell therapies. As CART19 enters routine clinical use, improving the efficacy of this exciting platform is the next step in broader application. Summary: Novel gene-editing technologies like CRISPR-Cas9 allow facile editing of specific genes within the genome, generating a powerful platform to further optimize the activity of engineered T cells.
AB - Purpose of Review: In this review, we discuss the most recent developments in gene-editing technology and discuss their application to adoptive T cell immunotherapy. Recent Findings: Engineered T cell therapies targeting cancer antigens have demonstrated significant efficacy in specific patient populations. Most impressively, CD19-directed chimeric antigen receptor T cells (CART19) have led to impressive responses in patients with B-cell leukemia and lymphoma. CTL019, or KYMRIAH™ (tisagenlecleucel), a CD19 CAR T cell product developed by Novartis and the University of Pennsylvania, was recently approved for clinical use by the Food and Drug Administration, representing a landmark in the application of adoptive T cell therapies. As CART19 enters routine clinical use, improving the efficacy of this exciting platform is the next step in broader application. Summary: Novel gene-editing technologies like CRISPR-Cas9 allow facile editing of specific genes within the genome, generating a powerful platform to further optimize the activity of engineered T cells.
KW - Adoptive cell therapy
KW - CRISPR-Cas9
KW - Chimeric antigen receptor T cells (CART)
KW - Gene-editing
KW - Immunotherapy
KW - PD-1
KW - TALEN
KW - Zinc-finger nucleases
UR - http://www.scopus.com/inward/record.url?scp=85031928323&partnerID=8YFLogxK
U2 - 10.1007/s11899-017-0417-7
DO - 10.1007/s11899-017-0417-7
M3 - Review article
C2 - 29039115
AN - SCOPUS:85031928323
SN - 1558-8211
VL - 12
SP - 522
EP - 529
JO - Current Hematologic Malignancy Reports
JF - Current Hematologic Malignancy Reports
IS - 6
ER -